These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22219158)

  • 1. Report from the 1st World Congress on Gallium-68 and Peptide Receptor Radio Nuclide Therapy (PRRNT), Bad Berka (Germany), June 23-26, 2011.
    Jurgilewicz D
    Nucl Med Rev Cent East Eur; 2011; 14(2):125-6. PubMed ID: 22219158
    [No Abstract]   [Full Text] [Related]  

  • 2. Peptide receptor radionuclide therapy of Merkel cell carcinoma using (177)lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology.
    Salavati A; Prasad V; Schneider CP; Herbst R; Baum RP
    Ann Nucl Med; 2012 May; 26(4):365-9. PubMed ID: 22361935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered biodistribution of somatostatin analogues after first cycle of Peptide receptor radionuclide therapy.
    Van Binnebeek S; Deroose CM; Baete K; Terwinghe C; Vanbilloen B; Koole M; Haustermans K; Mortelmans L; Verslype C; Van Cutsem E; Verbruggen A; Mottaghy FM
    J Clin Oncol; 2011 Jul; 29(19):e579-81. PubMed ID: 21555687
    [No Abstract]   [Full Text] [Related]  

  • 4. "Hevesy György" Hungarian Society of Nuclear Medicine. The XVIIth Congress in Budapest, May 25-27, 2011: a technologist's perspective.
    Peştean C
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39(2):380. PubMed ID: 22258745
    [No Abstract]   [Full Text] [Related]  

  • 5. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
    Kulkarni HR; Baum RP
    PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Peptide receptor radionuclide therapy of neuroendocrine tumors].
    Arveschoug AK; Hjorthaug K; Rehling M; Højgaard L; Mortensen J; Oturai PS
    Ugeskr Laeger; 2009 Mar; 171(13):1073. PubMed ID: 19321068
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of nuclear medicine in imaging infection.
    Auler MA; Bagg S; Gordon L
    Semin Roentgenol; 2007 Apr; 42(2):117-21. PubMed ID: 17394924
    [No Abstract]   [Full Text] [Related]  

  • 8. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.
    Bodei L; Pepe G; Paganelli G
    Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):347-51. PubMed ID: 20496546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Theranostics with Ga-68 somatostatin receptor PET/CT: monitoring response to peptide receptor radionuclide therapy.
    Kulkarni HR; Baum RP
    PET Clin; 2014 Jan; 9(1):91-7. PubMed ID: 25029938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; de Herder WW; Krenning EP
    Endocrinol Metab Clin North Am; 2011 Mar; 40(1):173-85, ix. PubMed ID: 21349418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear Medicine and its promising applications in gynecological cancers.
    Lioupis M; Syrmos NCh
    Hell J Nucl Med; 2016; 19(1):63. PubMed ID: 26929944
    [No Abstract]   [Full Text] [Related]  

  • 12. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
    Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A
    Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging in prostate cancer with multiparametric magnetic resonance imaging and gallium positron emission tomography-computed tomography: 'the real deal'?
    Lawrentschuk N
    BJU Int; 2015 Apr; 115 Suppl 5():1-2. PubMed ID: 25828170
    [No Abstract]   [Full Text] [Related]  

  • 14. DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice.
    Müller C; Struthers H; Winiger C; Zhernosekov K; Schibli R
    J Nucl Med; 2013 Jan; 54(1):124-31. PubMed ID: 23236020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving Important Role of Lutetium-177 for Therapeutic Nuclear Medicine.
    Pillai AM; Knapp FF
    Curr Radiopharm; 2015; 8(2):78-85. PubMed ID: 25771380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: first results of a multi-institutional cancer registry.
    Hörsch D; Ezziddin S; Haug A; Gratz KF; Dunkelmann S; Krause BJ; Schümichen C; Bengel FM; Knapp WH; Bartenstein P; Biersack HJ; Plöckinger U; Schwartz-Fuchs S; Baum RP
    Recent Results Cancer Res; 2013; 194():457-65. PubMed ID: 22918775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1 World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy (PRRNT), June 23-26, 2011, Zentralklinik Bad Berka, Germany.
    Baum RP; Rösch F
    World J Nucl Med; 2011 Jan; 10(1):1-2. PubMed ID: 22034575
    [No Abstract]   [Full Text] [Related]  

  • 18. Beyond 18F-FDG: Characterization of PET/CT and PET/MR Scanners for a Comprehensive Set of Positron Emitters of Growing Application--18F, 11C, 89Zr, 124I, 68Ga, and 90Y.
    Soderlund AT; Chaal J; Tjio G; Totman JJ; Conti M; Townsend DW
    J Nucl Med; 2015 Aug; 56(8):1285-91. PubMed ID: 26135111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial: Lutetium-177 Labeled Therapeutics: Emerging Importance for Cancer Treatment and Therapy of Chronic Disease.
    Knapp FF; Pillai AM
    Curr Radiopharm; 2015; 8(2):77. PubMed ID: 25771381
    [No Abstract]   [Full Text] [Related]  

  • 20. Molecular imaging: thriving all over the world.
    Wagner HN
    J Nucl Med; 2007 Aug; 48(8):15N-16N, 19N-38N. PubMed ID: 17673419
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.